Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis

Girardin, François; Poncet, Antoine; Blondon, Marc; Rollason, Victoria; Vernaz-Hegi, Nathalie; Chalandon, Yves; Dayer, Pierre; Combescure, Christophe

doi:10.1016/S2215-0366(14)70245-7

Scientific article

English

Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis

ContributorsGirardin, François; Poncet, Antoine; Blondon, Marc

; Rollason, Victoria; Vernaz-Hegi, Nathalie; Chalandon, Yves; Dayer, Pierre; Combescure, Christophe

Published inThe Lancet. Psychiatry, vol. 1, no. 1, p. 55-62

Publication date2014

Abstract

Long-term monitoring of white blood cell count is compulsory in patients taking clozapine, although the incidence of drug-induced agranulocytosis is lower than previously expected. The cost-effectiveness of this monitoring is unknown. We aimed to assess the cost-effectiveness of various strategies to monitor white blood cell count in adult patients with schizophrenia taking clozapine.

Affiliation entities

Research groups

Citation (ISO format)

GIRARDIN, François et al. Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. In: The Lancet. Psychiatry, 2014, vol. 1, n° 1, p. 55–62. doi: 10.1016/S2215-0366(14)70245-7

Article (Published version)

Identifiers

PID : unige:89789
DOI : 10.1016/S2215-0366(14)70245-7
PMID : 26360402

Journal ISSN2215-0366

561views

0downloads

Creation16/11/2016 15:57:00

First validation16/11/2016 15:57:00

Update15/03/2023 01:04:15

Status update15/03/2023 01:04:14

Last indexation19/11/2024 15:02:57

Archive ouverte UNIGE

Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis

Technical informations